Computer model to tell bone damage from cancer return after nasopharyngeal carcinoma radiotherapy
Tests a deep-learning model for telling skull-base bone damage from nasopharyngeal carcinoma recurrence.
Key facts
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Deep Learning-based sbORN Diagnostic Model
- Status
- Recruiting
- People taking part
- 312 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- No Intervention: Observational Cohort
- Record updated
- 1 October 2024
Who can take part
The trial is looking for adults treated with radiotherapy for nasopharyngeal carcinoma (a cancer behind the nose). Their scans must show possible bone damage at the skull base after radiotherapy. The study tests a computer model that tells this damage apart from cancer coming back.
- Age
- 18 years or older
- Sex
- All
- Disease stage
- Nonkeratinizing undifferentiated nasopharyngeal carcinoma, confirmed by tissue test. Complete remission (no visible cancer) six months after radiotherapy by RECIST 1.1. No spread to distant parts of the body at enrolment. A senior radiologist must suspect skull-base bone damage (sbORN), with a Likert score of 2-4.
- Earlier treatment
- Must have had radical radiotherapy to the nasopharynx.
- Biomarker or test result
- Must agree to blood tests, EBV DNA, EBV IgAs, MRI of the nasopharynx and neck, and a biopsy, done awake or under general anesthesia.
- Main reasons for not taking part
- MRI artifacts or other problems that make the scans hard to read
- Suspected lesion reaches beyond the nasopharynx and skull base
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Equal to or older than 18 years old
- A history of histologically confirmed nonkeratinizing undifferentiated nasopharyngeal carcinoma
- A history of radical radiotherapy at nasopharynx
- Complete remission six months post radical radiotherapy according to RECIST 1.1
- No evidence of distant metastasis upon recruitment
- Diagnosis of sbORN given by senior radiologist with 2-4 Likert scores
- Consent to biopsy awake or under general anesthesia
- Consent to perform blood tests, EBV DNA, EBV IgAs, and MRI inspection of nasopharynx and neck
- With a written consent
Who cannot take part
- MRI artifacts or other factors that interfere radiological diagnosis and region of interest contouring
- Suspected lesion is not confined to nasopharynx and skull-base
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Nasopharyngeal carcinoma
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.
The 2 groups in the trial
- Case
Histologically confirmed sbORN that meets the eligibility criteria.
Treatment: No Intervention: Observational Cohort
- Control
Histologically confirmed NPC recurrence that meets the eligibility criteria.
Treatment: No Intervention: Observational Cohort
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development of Deep-Learning-Based Multimodal Post Radiotherapy Skull-Base Osteonecrosis and Recurrence of Nasopharyngeal Carcinoma Differential Diagnostic Model
- Plain-language title
- Computer model to tell bone damage from cancer return after nasopharyngeal carcinoma radiotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06463392, who can take part
- Record updated
- 1 October 2024